Revvity (NYSE:RVTY) Downgraded by Zacks Research to Strong Sell

Revvity (NYSE:RVTY) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also recently issued reports about the company. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Evercore reaffirmed an “outperform” rating and set a $125.00 target price on shares of Revvity in a research note on Monday. Weiss Ratings raised shares of Revvity from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 24th. Barclays upped their price objective on shares of Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, Stifel Nicolaus dropped their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a report on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Revvity has a consensus rating of “Hold” and a consensus price target of $108.92.

Revvity Stock Performance

NYSE:RVTY opened at $112.15 on Monday. The company’s 50-day moving average is $100.42 and its two-hundred day moving average is $98.36. The firm has a market capitalization of $12.51 billion, a price-to-earnings ratio of 53.66, a PEG ratio of 2.47 and a beta of 1.09. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.72 and a quick ratio of 1.41. Revvity has a 1-year low of $81.22 and a 1-year high of $118.30.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $711.12 million for the quarter, compared to analysts’ expectations of $704.07 million. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.01 earnings per share. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Analysts forecast that Revvity will post 5.25 EPS for the current year.

Institutional Trading of Revvity

Several hedge funds have recently modified their holdings of RVTY. AQR Capital Management LLC increased its holdings in Revvity by 5.2% during the 1st quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock worth $883,000 after purchasing an additional 420 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Revvity by 6.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock valued at $1,246,000 after buying an additional 744 shares during the period. Millennium Management LLC grew its position in shares of Revvity by 102.0% during the first quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock worth $7,343,000 after buying an additional 35,048 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Revvity by 45.5% during the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock worth $64,232,000 after buying an additional 189,871 shares during the period. Finally, Focus Partners Wealth raised its holdings in Revvity by 13.0% in the first quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock valued at $744,000 after acquiring an additional 811 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.